SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

- Presentation at ASH will Feature Results from the Phase 2a Trial of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia After Venetoclax Failure –

- 50% Response Rate at the Selected Dose Level of 30 mg Twice a Week (BIW) –

Read more at globenewswire.com